B7-H3/CD276: An Emerging Cancer Immunotherapy

^{Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai, China,}

^{Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou, China,}

Edited by: Mingzhu Yin, Central South University, China

Reviewed by: Wenping Ma, Capital Medical University, China; Lisa Sevenich, Georg Speyer Haus, Germany

*Correspondence: Wei-Lin Jin, nc.ude.uzl@lwnij_yydl; moc.oohay@nijniliew

This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Edited by: Mingzhu Yin, Central South University, China

Reviewed by: Wenping Ma, Capital Medical University, China; Lisa Sevenich, Georg Speyer Haus, Germany

Received 2021 Apr 27; Accepted 2021 Jul 5.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Abstract

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy.

Keywords: B7-H3/CD276, immune checkpoint, tumor microenvironment, tumor immunology, cancer immunotherapy

Abstract

Not all clinical studies were included in this table due to the space limitation.

References

1. Egen JG, Ouyang W, Wu LC. Human Anti-Tumor Immunity: Insights From Immunotherapy Clinical Trials. Immunity (2020) 52:36–54. 10.1016/j.immuni.2019.12.010 [] [[PubMed]
2. Sanmamed MF, Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell (2018) 175:313–26. 10.1016/j.cell.2018.09.035 ] [
3. Li G, Quan Y, Che F, Wang L. B7-H3 in Tumors: Friend or Foe for Tumor Immunity? Cancer Chemother Pharmacol (2018) 81:245–53. 10.1007/s00280-017-3508-1 [] [[PubMed]
4. Loos M, Hedderich DM, Friess H, Kleeff J. B7-H3 and Its Role in Antitumor Immunity. Clin Dev Immunol (2010) 2010:683875. 10.1155/2010/683875 ] [
5. Pollizzi KN, Powell JD. Integrating Canonical and Metabolic Signalling Programmes in the Regulation of T Cell Responses. Nat Rev Immunol (2014) 14:435–46. 10.1038/nri3701 ] [
6. Zang X, Allison JP. The B7 Family and Cancer Therapy: Costimulation and Coinhibition. Clin Cancer Res (2007) 13:5271–9. 10.1158/1078-0432.CCR-07-1030 [] [[PubMed]
7. Hofmeyer KA, Ray A, Zang X. The Contrasting Role of B7-H3. Proc Natl Acad Sci USA (2008) 105:10277–8. 10.1073/pnas.0805458105 ] [
8. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. . B7-H3: A Costimulatory Molecule for T Cell Activation and IFN-Gamma Production. Nat Immunol (2001) 2:269–74. 10.1038/85339 [] [[PubMed]
9. Zou W, Chen L. Inhibitory B7-Family Molecules in the Tumour Microenvironment. Nat Rev Immunol (2008) 8:467–77. 10.1038/nri2326 [] [[PubMed]
10. Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of Mouse and Human B7-H3 Genes. J Immunol (2002) 168:6294–7. 10.4049/jimmunol.168.12.6294 [] [[PubMed]
11. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, et al. . Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family With Four Ig-like Domains. J Immunol (2004) 172:2352–9. 10.4049/jimmunol.172.4.2352 [] [[PubMed]
12. Chen W, Liu P, Wang Y, Nie W, Li Z, Xu W, et al. . Characterization of a Soluble B7-H3 (sB7-H3) Spliced From the Intron and Analysis of sB7-H3 in the Sera of Patients With Hepatocellular Carcinoma. PloS One (2013) 8:e76965. 10.1371/journal.pone.0076965 ] [
13. Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7-H3) is Released From Monocytes, Dendritic Cells and Activated T Cells and is Detectable in Normal Human Serum. Immunology (2008) 123:538–46. 10.1111/j.1365-2567.2007.02723.x ] [
14. Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad O, Nunes-Xavier CE. Immunoregulatory Protein B7-H3 Promotes Growth and Decreases Sensitivity to Therapy in Metastatic Melanoma Cells. Pigm Cell Melanoma R (2017) 30:467–76. 10.1111/pcmr.12599 [] [[PubMed]
15. Purvis IJ, Velpula KK, Guda MR, Nguyen D, Tsung AJ, Asuthkar S. B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role. Int J Mol Sci (2020) 21:7050. 10.3390/ijms21197050 ] [
16. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H, Azuma M. Triggering Receptor Expressed on Myeloid Cell-Like Transcript 2 (TLT-2) is a Counter-Receptor for B7-H3 and Enhances T Cell Responses. P Natl Acad Sci USA (2008) 105:14744–4. 10.1073/pnas.0807700105. (vol 105, pg 10495, 2008). ] [
17. Yang S, Wei W, Zhao Q. B7-H3, a Checkpoint Molecule, as a Target for Cancer Immunotherapy. Int J Biol Sci (2020) 16:1767–73. 10.7150/ijbs.41105 ] [
18. Picarda E, Ohaegbulam KC, Zang X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res (2016) 22:3425–31. 10.1158/1078-0432.CCR-15-2428 ] [
19. Flem-Karlsen K, Fodstad O, Tan M, Nunes-Xavier CE. B7-H3 in Cancer - Beyond Immune Regulation. Trends Cancer (2018) 4:401–4. 10.1016/j.trecan.2018.03.010 [] [[PubMed]
20. Wang L, Kang FB, Sun N, Wang J, Chen W, Li D, et al. . The Tumor Suppressor miR-124 Inhibits Cell Proliferation and Invasion by Targeting B7-H3 in Osteosarcoma. Tumour Biol (2016) 37:14939–47. 10.1007/s13277-016-5386-2 [] [[PubMed]
21. Purvis IJ, Avilala J, Guda MR, Venkataraman S, Vibhakar R, Tsung AJ, et al. . Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis. J Clin Med (2019) 8:1158. 10.3390/jcm8081158 ] [
22. Hu X, Xu M, Hu Y, Li N, Zhou L. B7-H3, Negatively Regulated by Mir-128, Promotes Colorectal Cancer Cell Proliferation and Migration. Cell Biochem Biophys (2021) 79:397–405. 10.1007/s12013-021-00975-0 [] [[PubMed]
23. Cong F, Yu H, Gao X. Expression of CD24 and B7-H3 in Breast Cancer and the Clinical Significance. Oncol Lett (2017) 14:7185–90. 10.3892/ol.2017.7142 ] [
24. Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, et al. . B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. Clin Cancer Res (2018) 24:2653–64. 10.1158/1078-0432.CCR-17-2852 [] [[PubMed]
25. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al. . Tumor Associated Endothelial Expression of B7-H3 Predicts Survival in Ovarian Carcinomas. Mod Pathol (2010) 23:1104–12. 10.1038/modpathol.2010.95 ] [
26. Proctor DT, Patel Z, Lama S, Resch L, van Marle G, Sutherland GR. Identification of PD-L2, B7-H3 and CTLA-4 Immune Checkpoint Proteins in Genetic Subtypes of Meningioma. Oncoimmunology (2019) 8:e1512943. 10.1080/2162402X.2018.1512943 ] [
27. Deng J, Ma M, Wang D, Zhu H, Hua L, Sun S, et al. . Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma. World Neurosurg (2020) 135:e12–8. 10.1016/j.wneu.2019.10.044 [] [[PubMed]
28. Li Y, Yang X, Wu Y, Zhao K, Ye Z, Zhu J, et al. . B7-H3 Promotes Gastric Cancer Cell Migration and Invasion. Oncotarget (2017) 8:71725–35. 10.18632/oncotarget.17847 ] [
29. Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE. Roles of Coinhibitory Molecules B7-H3 and B7-H4 in Esophageal Squamous Cell Carcinoma. Tumour Biol (2016) 37:2961–71. 10.1007/s13277-015-4132-5 [] [[PubMed]
30. Varki V, Ioffe OB, Bentzen SM, Heath J, Cellini A, Feliciano J, et al. . Pd-L1, B7-H3, and PD-1 Expression in Immunocompetent vs. Immunosuppressed Patients With Cutaneous Squamous Cell Carcinoma. Cancer Immunol Immunother (2018) 67:805–14. 10.1007/s00262-018-2138-8 [] [[PubMed]
31. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. . Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. Int J Cancer (2015) 136:E359–386. 10.1002/ijc.29210 [] [[PubMed]
32. Wilson KE, Bachawal SV, Abou-Elkacem L, Jensen K, Machtaler S, Tian L, et al. . Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer Using a B7-H3-targeted Icg Contrast Agent. Theranostics (2017) 7:1463–76. 10.7150/thno.18217 ] [
33. Arigami T, Narita N, Mizuno R, Nguyen L, Ye X, Chung A, et al. . B7-H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis. Ann Surg (2010) 252:1044–51. 10.1097/SLA.0b013e3181f1939d [] [[PubMed]
34. Castellanos JR, Purvis IJ, Labak CM, Guda MR, Tsung AJ, Velpula KK, et al. . B7-H3 Role in the Immune Landscape of Cancer. Am J Clin Exp Immunol (2017) 6:66–75.
35. Li F, Chen H, Wang D. Silencing of CD276 Suppresses Lung Cancer Progression by Regulating Integrin Signaling. J Thorac Dis (2020) 12:2137–45. 10.21037/jtd.2020.04.41 ] [
36. MacGregor HL, Sayad A, Elia A, Wang BX, Katz SR, Shaw PA, et al. . High Expression of B7-H3 on Stromal Cells Defines Tumor and Stromal Compartments in Epithelial Ovarian Cancer and Is Associated With Limited Immune Activation. J Immunother Cancer (2019) 7:357. 10.1186/s40425-019-0816-5 ] [
37. Cai DL, Li JM, Liu DF, Hong SJ, Qiao Q, Sun QL, et al. . Tumor-Expressed B7-H3 Mediates the Inhibition of Antitumor T-Cell Functions in Ovarian Cancer Insensitive to PD-1 Blockade Therapy. Cell Mol Immunol (2020) 17:227–36. 10.1038/s41423-019-0305-2 ] [
38. Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et al. . Car T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res (2019) 25:2560–74. 10.1158/1078-0432.CCR-18-0432 [] [[PubMed]
39. Wang ZX, Yang JF, Zhu YB, Zhu Y, Zhang B, Zhou YH. Differential Expression of 2igB7-H3 and 4igB7-H3 in Cancer Cell Lines and Glioma Tissues. Oncol Lett (2015) 10:2204–8. 10.3892/ol.2015.3611 ] [
40. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, et al. . B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates With Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res (2019) 25:3455–67. 10.1158/1078-0432.CCR-18-2355 ] [
41. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, Dawicki W, et al. . The B7 Family Member B7-H3 Preferentially Down-Regulates T Helper Type 1-Mediated Immune Responses. Nat Immunol (2003) 4:899–906. 10.1038/ni967 [] [[PubMed]
42. Suh WK, Wang SX, Jheon AH, Moreno L, Yoshinaga SK, Ganss B, et al. . The Immune Regulatory Protein B7-H3 Promotes Osteoblast Differentiation and Bone Mineralization. Proc Natl Acad Sci USA (2004) 101:12969–73. 10.1073/pnas.0405259101 ] [
43. Lupu CM, Eisenbach C, Kuefner MA, Schmidt J, Lupu AD, Stremmel W, et al. . An Orthotopic Colon Cancer Model for Studying the B7-H3 Antitumor Effect In Vivo. J Gastrointest Surg (2006) 10:635–45. 10.1007/BF03239969 [] [[PubMed]
44. Lupu CM, Eisenbach C, Lupu AD, Kuefner MA, Hoyler B, Stremmel W, et al. . Adenoviral B7-H3 Therapy Induces Tumor Specific Immune Responses and Reduces Secondary Metastasis in a Murine Model of Colon Cancer. Oncol Rep (2007) 18:745–8. 10.3892/or.18.3.745 [] [[PubMed]
45. Prasad DVR, Nguyen T, Li ZX, Yang Y, Duong J, Wang Y, et al. . Murine B7-H3 is a Negative Regulator of T Cells. J Immunol (2004) 173:2500–6. 10.4049/jimmunol.173.4.2500 [] [[PubMed]
46. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, et al. . Identification of 4Ig-B7-H3 as a Neuroblastoma-Associated Molecule That Exerts a Protective Role From an NK Cell-Mediated Lysis. Proc Natl Acad Sci USA (2004) 101:12640–5. 10.1073/pnas.0405025101 ] [
47. Wang C, Li Y, Jia L, Kim JK, Li J, Deng P, et al. . CD276 Expression Enables Squamous Cell Carcinoma Stem Cells to Evade Immune Surveillance. Cell Stem Cell (2021) 28:1–17. 10.1016/j.stem.2021.04.011 [] [[PubMed]
48. Jin MZ, Jin WL. The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduct Target Ther (2020) 5:166. 10.1038/s41392-020-00280-x ] [
49. Li H, Zhang B, Liu Y, Yin C. EBP50 Inhibits the Migration and Invasion of Human Breast Cancer Cells Via LIMK/Cofilin and the PI3K/Akt/mTOR/MMP Signaling Pathway. Med Oncol (2014) 31:162. 10.1007/s12032-014-0162-x [] [[PubMed]
50. Niu H, Wu B, Peng Y, Jiang H, Zhang Y, Wang J, et al. . RNA Interference-Mediated Knockdown of RhoGDI2 Induces the Migration and Invasion of Human Lung Cancer A549 Cells Via Activating the PI3K/Akt Pathway. Tumour Biol (2015) 36:409–19. 10.1007/s13277-014-2671-9 [] [[PubMed]
51. Wu XY, Chen Y, Li G, Xia L, Gu RM, Wen X, et al. . Her3 is Associated With Poor Survival of Gastric Adenocarcinoma: Her3 Promotes Proliferation, Survival and Migration of Human Gastric Cancer Mediated by PI3K/AKT Signaling Pathway. Med Oncol (2014) 31:1–11. 10.1007/s12032-014-0903-x [] [[PubMed]
52. El Hage A, Dormond O. Combining Mtor Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment. Cancers (Basel) (2021) 13:1359. 10.3390/cancers13061359 ] [
53. Li YC, Guo GN, Song J, Cai ZP, Yang J, Chen ZW, et al. . B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells Via the PI3K/Akt/STAT3 Signaling Pathway. J Cancer (2017) 8:816–24. 10.7150/jca.17759 ] [
54. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Oyjord T, Hongisto V, et al. . Decreased Expression of B7-H3 Reduces the Glycolytic Capacity and Sensitizes Breast Cancer Cells to AKT/mTOR Inhibitors. Oncotarget (2016) 7:6891–901. 10.18632/oncotarget.6902 ] [
55. Jiang B, Zhang T, Liu F, Sun ZZ, Shi HP, Hua D, et al. . The Co-Stimulatory Molecule B7-H3 Promotes the Epithelial-Mesenchymal Transition in Colorectal Cancer. Oncotarget (2016) 7:31755–71. 10.18632/oncotarget.9035 ] [
56. Napetschnig J, Wu H. Molecular Basis of NF-kappaB Signaling. Annu Rev Biophys (2013) 42:443–68. 10.1146/annurev-biophys-083012-130338 ] [
57. Wang RQ, Ma YC, Zhan SH, Zhang GB, Cao L, Zhang XG, et al. . B7-H3 Promotes Colorectal Cancer Angiogenesis Through Activating the NF-Kappa B Pathway to Induce VEGFA Expression. Cell Death Dis (2020) 11:55. 10.1038/s41419-020-2252-3 ] [
58. Xie C, Liu DQ, Chen QJ, Yang C, Wang B, Wu HS. Soluble B7-H3 Promotes the Invasion and Metastasis of Pancreatic Carcinoma Cells Through the TLR4/NF-Kappa B Pathway. Sci Rep (2016) 6:27528. 10.1038/srep27528 ] [
59. Qi MS, Elion EA. MAP Kinase Pathways. J Cell Sci (2005) 118:3569–72. 10.1242/jcs.02470 [] [[PubMed]
60. Flem-Karlsen K, Tekle C, Oyjord T, Florenes VA, Maelandsmo GM, Fodstad O, et al. . P38 MAPK Activation Through B7-H3-Mediated DUSP10 Repression Promotes Chemoresistance. Sci Rep-Uk (2019) 9:5839. 10.1038/s41598-019-42303-w ] [
61. Girardi T, Sulima SO, Vereecke S, Khan Y, Fancello L, Flickinger Z, et al. . The T-Cell Leukemia Associated Ribosomal Rpl10 R98s Mutation Enhances Jak-Stat Signaling. Haematologica (2017) 102:159–9. 10.1038/leu.2017.225 ] [
62. Raible DJ, Frey LC, Brooks-Kayal AR. Effects of JAK2-STAT3 Signaling After Cerebral Insults. JAKSTAT (2014) 3:e29510. 10.4161/jkst.29510 ] [
63. Capalbo G, Dittmann K, Hausmann E, Weiss C, Rodel C, Rodel F. Survivin As A Novel Target Protein for Reducing the Proliferation of Cancer Cells. Strahlenther Onkol (2009) 185:157–7. 10.3892/br.2018.1077 [[PubMed]
64. Buki A, Okonkwo DO, Wang KKW, Povlishock JT. Cytochrome C Release and Caspase Activation in Traumatic Axonal Injury. J Neurosci (2000) 20:2825–34. 10.1523/JNEUROSCI.20-08-02825.2000 ] [
65. Liu H, Tekle C, Chen YW, Kristian A, Zhao YH, Zhou M, et al. . B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation. Mol Cancer Ther (2011) 10:960–71. 10.1158/1535-7163.Mct-11-0072 ] [
66. Zhang T, Jiang B, Zou ST, Liu F, Hua D. Overexpression of B7-H3 Augments Anti-Apoptosis of Colorectal Cancer Cells by Jak2-STAT3. World J Gastroenterol (2015) 21:1804–13. 10.3748/wjg.v21.i6.1804 ] [
67. Lu H, Ma Y, Wang M, Shen J, Wu H, Li J, et al. . B7-H3 Confers Resistance to Vgamma9Vdelta2 T Cell-Mediated Cytotoxicity in Human Colon Cancer Cells Via the STAT3/ULBP2 Axis. Cancer Immunol Immunother (2021) 70:1213–26. 10.1007/s00262-020-02771-w [] [[PubMed]
68. Yang SY, Sales KM, Fuller B, Seifalian AM, Winslet MC. Apoptosis and Colorectal Cancer: Implications for Therapy. Trends Mol Med (2009) 15:225–33. 10.1016/j.molmed.2009.03.003 [] [[PubMed]
69. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144:646–74. 10.1016/j.cell.2011.02.013 [] [[PubMed]
70. Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science (2009) 324:1029–33. 10.1126/science.1160809 ] [
71. Lim S, Liu H, da Silva LM, Arora R, Liu ZX, Phillips JB, et al. . Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1 Alpha. Cancer Res (2016) 76:2231–42. 10.1158/0008-5472.Can-15-1538 ] [
72. Shi T, Ma Y, Cao L, Chen W, Zhang X. B7-H3 Promotes Aerobic Glycolysis and Chemoresistance in Colorectal Cancer Cells by Regulating HK2. Eur J Immunol (2019) 49:95–5. 10.1038/s41419-019-1549-6 ] [
73. Michelakos T, Kontos F, Barakat O, Maggs L, Schwab JH, Ferrone CR, et al. . B7-H3 Targeted Antibody-Based Immunotherapy of Malignant Diseases. Expert Opin Biol Ther (2021) 21:587–602. 10.1080/14712598.2021.1862791 ] [
74. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. . Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer. New Engl J Med (2012) 366:2455–65. 10.1056/NEJMoa1200694 ] [
75. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. . Improved Survival With Ipilimumab in Patients With Metastatic Melanoma. N Engl J Med (2010) 363:711–23. 10.1056/NEJMoa1003466 ] [
76. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. . Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med (2012) 366:2443–54. 10.1056/NEJMoa1200690 ] [
77. Lee YH, Martin-Orozco N, Zheng PL, Li J, Zhang P, Tan HD, et al. . Inhibition of the B7-H3 Immune Checkpoint Limits Tumor Growth by Enhancing Cytotoxic Lymphocyte Function. Cell Res (2017) 27:1034–45. 10.1038/cr.2017.90 ] [
78. Lu H, Shi T, Wang M, Li X, Gu Y, Zhang X, et al. . B7-H3 Inhibits the IFN-gamma-dependent Cytotoxicity of Vgamma9Vdelta2 T Cells Against Colon Cancer Cells. Oncoimmunology (2020) 9:1748991. 10.1080/2162402X.2020.1748991 ] [
79. Loo D, Alderson RF, Chen FZ, Huang L, Zhang WJ, Gorlatov S, et al. . Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody With Potent Antitumor Activity. Clin Cancer Res (2012) 18:3834–45. 10.1158/1078-0432.Ccr-12-0715 [] [[PubMed]
80. Scribner JA, Brown JG, Sharma S, Li H, Chiechi M, Li P, et al. . Preclinical Development of MGC018, a Duocarmycin-Based Antibody-Drug Conjugate Targeting B7-H3 for Solid Cancer. Cancer Res (2018) 78:820. 10.1158/1538-7445.AM2018-820 [] [[PubMed]
81. Weidle UH, Kontermann RE, Brinkmann U. Tumor-Antigen-Binding Bispecific Antibodies for Cancer Treatment. Semin Oncol (2014) 41:653–60. 10.1053/j.seminoncol.2014.08.004 [] [[PubMed]
82. Ma J, Ma P, Zhao CH, Xue X, Han HM, Liu CZ, et al. . B7-H3 as a Promising Target for Cytotoxicity T Cell in Human Cancer Therapy. Oncotarget (2016) 7:29480–91. 10.18632/oncotarget.8784 ] [
83. Watchorn E. Irradiated Ergosterol and Calcium-Free Diet: Effect on Calcium and Phosphorus Metabolism. Biochem J (1930) 24:1560–3. 10.1042/bj0241560 ] [
84. Davis ZB, Vallera DA, Miller JS, Felices M. Natural Killer Cells Unleashed: Checkpoint Receptor Blockade and BiKE/TriKE Utilization in NK-mediated Anti-Tumor Immunotherapy. Semin Immunol (2017) 31:64–75. 10.1016/j.smim.2017.07.011 ] [
85. Kontos F, Kurokawa T, Vallera DA, Ferrone S, Ferrone CR. Il-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. J Am Coll Surgeons (2019) 229:S176–6. 10.1016/j.jamcollsurg.2019.08.388 [[PubMed]
86. Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, et al. . Nk-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. Cancers (2020) 12:2659. 10.3390/cancers12092659 ] [
87. Adams JL, Smothers J, Srinivasan R, Hoos A. Big Opportunities for Small Molecules in Immuno-Oncology. Nat Rev Drug Discovery (2015) 14:603–22. 10.1038/nrd4596 [] [[PubMed]
88. Vigdorovich V, Ramagopal UA, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, et al. . Structure and T Cell Inhibition Properties of B7 Family Member. B7-H3 Struct (2013) 21:707–17. 10.1016/j.str.2013.03.003 ] [
89. Chen S, Song Z, Zhang A. Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. Curr Top Med Chem (2019) 19:180–5. 10.2174/1568026619666190308131805 [] [[PubMed]
90. Tang X, Wang YL, Huang JH, Zhang ZL, Liu FJ, Xu JG, et al. . Administration of B7-H3 Targeted Chimeric Antigen Receptor-T Cells Induce Regression of Glioblastoma. Signal Transduction Targeted Ther (2021) 6:125. 10.1038/s41392-021-00505-7 ] [
91. Nehama D, Di Ianni N, Musio S, Du HW, Patane M, Polloc B, et al. . B7-H3-redirected Chimeric Antigen Receptor T Cells Target Glioblastoma and Neurospheres. Ebiomedicine (2019) 47:33–43. 10.1016/j.ebiom.2019.08.030 ] [
92. Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, et al. . Locoregionally Administered B7-H3-Targeted Car T Cells for Treatment of Atypical Teratoid/Rhabdoid Tumors. Nat Med (2020) 26:712–+. 10.1038/s41591-020-0821-8 ] [
93. Yang MJ, Tang X, Zhang ZL, Gu L, Wei H, Zhao SS, et al. . Tandem CAR-T Cells Targeting CD70 and B7-H3 Exhibit Potent Preclinical Activity Against Multiple Solid Tumors. Theranostics (2020) 10:7622–34. 10.7150/thno.43991 ] [
94. Tang X, Liu FJ, Liu ZY, Cao Y, Zhang ZL, Wang YL, et al. . Bioactivity and Safety of B7-H3-targeted Chimeric Antigen Receptor T Cells Against Anaplastic Meningioma. Clin Trans Immunol (2020) 9:e1137. 10.1002/cti2.1137 ] [
95. Yang S, Cao BH, Zhou GY, Zhu LP, Wang L, Zhang L, et al. . Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer. Front Pharmacol (2020) 11:1089. 10.3389/fphar.2020.01089 ] [
96. Lei X, Ou Z, Yang Z, Zhong J, Zhu Y, Tian J, et al. . A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific Car-T Cells in Solid Tumors. Clin Cancer Res (2021) 27:3757–71. 10.1158/1078-0432.CCR-20-2487 [] [[PubMed]
97. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New Engl J Med (2015) 373:23–34. 10.1056/NEJMoa1504030 ] [
98. Xu Y, Xiao Y, Luo C, Liu QX, Wei AQ, Yang Y, et al. . Blocking PD-1/PD-L1 by an ADCC Enhanced anti-B7-H3/PD-1 Fusion Protein Engages Immune Activation and Cytotoxicity. Int Immunopharmacol (2020) 84. 10.1016/j.intimp.2020.106584 [] [[PubMed]
99. Zhang W, Wang J, Wang YF, Dong F, Zhu MX, Wan WL, et al. . B7-H3 Silencing by RNAi Inhibits Tumor Progression and Enhances Chemosensitivity in U937 Cells. Oncotargets Ther (2015) 8:1721–33. 10.2147/OTT.S85272 ] [
100. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. . Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature (2015) 520:373–7. 10.1038/nature14292 ] [
101. Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, et al. . Humanized Affinity-Matured Monoclonal Antibody 8h9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem (2015) 290:30018–29. 10.1074/jbc.M115.679852 ] [
102. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity (2020) 52:17–35. 10.1016/j.immuni.2019.12.011 [] [[PubMed]
103. White AA, Lee DN, Mazzola E, Kucukak S, Polhemus E, Jaklitsch MT, et al. . Adjuvant Therapy Following Induction Therapy and Surgery Improves Survival in N2-Positive Non-Small Cell Lung Cancer. J Surg Oncol (2021) 123:579–86. 10.1002/jso.26305 [] [[PubMed]
104. Minami Y, Nishida N, Kudo M. Radiofrequency Ablation of Liver Metastasis: Potential Impact on Immune Checkpoint Inhibitor Therapy. Eur Radiol (2019) 29:5045–51. 10.1007/s00330-019-06189-6 [] [[PubMed]
105. Bialosky JE, Beneciuk JM, Bishop MD, Coronado RA, Penza CW, Simon CB, et al. . Unraveling the Mechanisms of Manual Therapy: Modeling an Approach. J Orthop Sports Phys Ther (2018) 48:8–18. 10.2519/jospt.2018.7476 [] [[PubMed]
106. Lei KF, Ji WW, Goh A, Huang CH, Lee MY. Investigation of Uniform Sized Multicellular Spheroids Raised by Microwell Arrays After the Combined Treatment of Electric Field and Anti-Cancer Drug. BioMed Microdevices (2019) 21:94. 10.1007/s10544-019-0442-5 [] [[PubMed]